CLLS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Cellectis SA

NASDAQ | CLLS

4.51

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 16, 2025)

$433.02M

Market Cap

-

P/E Ratio

-0.59

EPS

$4.58

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

CLLS Chart

Recent Chart
Price Action

CLLS Technicals

Tags:

CLLS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $22M
Total Revenue $42M
Cost Of Revenue $20M
Costof Goods And Services Sold $20M
Operating Income -$60M
Selling General And Administrative $18M
Research And Development $91M
Operating Expenses $90M
Investment Income Net -
Net Interest Income $3.8M
Interest Income $11M
Interest Expense $7.5M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $20M
Income Before Tax -$43M
Income Tax Expense -$6.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$37M
Comprehensive Income Net Of Tax -
Ebit -$36M
Ebitda -$16M
Net Income -$37M

Revenue & Profitability

Earnings Performance

CLLS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $384M
Total Current Assets $287M
Cash And Cash Equivalents At Carrying Value $143M
Cash And Short Term Investments $143M
Inventory -
Current Net Receivables $23M
Total Non Current Assets $96M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.1M
Intangible Assets Excluding Goodwill $1.1M
Goodwill -
Investments -
Long Term Investments $7.5M
Short Term Investments $117M
Other Current Assets $3.7M
Other Non Current Assets -
Total Liabilities $253M
Total Current Liabilities $166M
Current Accounts Payable $19M
Deferred Revenue -
Current Debt -
Short Term Debt $13M
Total Non Current Liabilities $95M
Capital Lease Obligations $43M
Long Term Debt $44M
Current Long Term Debt $4.8M
Long Term Debt Noncurrent -
Short Long Term Debt Total $91M
Other Current Liabilities $22M
Other Non Current Liabilities $882K
Total Shareholder Equity $131M
Treasury Stock -
Retained Earnings -$330M
Common Stock $5.9M
Common Stock Shares Outstanding $91M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $23M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $20M
Capital Expenditures $3.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$103M
Cashflow From Financing $89M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $0
Dividend Payout Common Stock $0
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$37M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $22M
Total Revenue $42M
Cost Of Revenue $20M
Costof Goods And Services Sold $20M
Operating Income -$60M
Selling General And Administrative $18M
Research And Development $91M
Operating Expenses $90M
Investment Income Net -
Net Interest Income $3.8M
Interest Income $11M
Interest Expense $7.5M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $20M
Income Before Tax -$43M
Income Tax Expense -$6.4M
Interest And Debt Expense -
Net Income From Continuing Operations -$37M
Comprehensive Income Net Of Tax -
Ebit -$36M
Ebitda -$16M
Net Income -$37M

CLLS News

CLLS Profile

Cellectis SA Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Cellectis SA is a clinical-stage biotechnology firm headquartered in Paris, France, specializing in the development of innovative immuno-oncology therapies utilizing its proprietary gene-editing platform. By leveraging its cutting-edge technology, the company creates T cell therapies that incorporate chimeric antigen receptors (CARs) to effectively target and eliminate cancer cells. With a diverse pipeline of candidates at various clinical development stages and strategic partnerships, Cellectis is strategically positioned to transform cancer treatment, addressing critical unmet medical needs and aiming to improve patient outcomes significantly.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
MARA
-11.62%
$20.18
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-13.85%
$0.51
QS
-13.41%
$15.45
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
RXRX
-7.21%
$6.29
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
ONDS
-13.77%
$8.19
IONZ
+18.46%
$3.41
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
GDXD
-7.91%
$0.61
MARA
-11.62%
$20.18
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
VSEE
-13.85%
$0.51
QS
-13.41%
$15.45
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
QSI
-3.23%
$2.54
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
QUBT
-12.12%
$18.65
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
IREN
-8.94%
$61.89
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
NOK
+0.53%
$5.68
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
TOVX
-47.86%
$0.43
KDLY
+1.29%
$0.79
SLNH
-1.39%
$4.23
AMC
-2.12%
$2.76
AMZN
-0.81%
$213.82
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.